Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06702033 · ClinicalTrials.gov registry record · Phase 2
The Minimalist Trial-2
A Phase 2 study of HPV-Related Oropharynx Squamous Cell Carcinoma, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 142
- Enrollment target
- 1
- Study location
NCT06702033 is a Phase 2 study of HPV-Related Oropharynx Squamous Cell Carcinoma that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 142 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06702033, a Phase 2 study of HPV-Related Oropharynx Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 142 participants
- Enrollment target
- 1
- Study location
Study Summary
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer. Oropharynx SCC (OPSCC) is a common sub-type of HNSCC. Each year, 16,000 new cases of OPSCC are diagnosed in the USA. Most cases of OPSCC (\>90%) are caused by the human papillomavirus (HPV) and are often cured with current therapy. However, patients treated with surgery followed by postoperative adjuvant chemotherapy and radiation therapy (POA(C)RT) still experience substantial morbidity. In this highly curable disease, current clinical research interest is focused on investigation of de-escalated therapy, with the goal to reduce treatment-related adverse events (AEs) while maintaining a low recurrence rate. In this study, patients with HPV-related OPSCC will undergo resection of the primary tumor site and involved/at-risk regional neck nodes. Based on the pathology report, patients will be assigned to: * Arm 1 (de-POACRT-42 Gy) * Arm 2A (de-POART-42 Gy) * Arm 2B (de-POART-37.8 Gy) * Arm 2C (de-POACRT-30 Gy). All patients with high-risk pathology will be assigned to Arm 1 whereas patients with intermediate-risk pathology will be randomized (1:1:1) to Arm 2A, Arm 2B, or Arm 2C. Patients with highest-risk pathology and low-risk pathology will be removed from the trial after surgery and will be advised to pursue standard of care options.
Conditions Studied
Interventions
- DRUG Cisplatin
- PROCEDURE Surgery
- RADIATION Radiation therapy
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2025-04-10 |
| Est. Completion | 2033-07-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06702033
The ClinicalTrials.gov registry entry for NCT06702033 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HPV-Related Oropharynx Squamous Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Cisplatin is the first listed.
NCT06702033 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT06702033 about?
NCT06702033 is a clinical study titled "The Minimalist Trial-2". Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer. Oropharynx SCC (OPSCC) is a common sub-type of HNSCC. Each year, 16,000 new cases of OPSCC are diagnosed in the USA. Most cases of OPSCC (\>90%) are caused by the human papillomavirus (HPV) and are often cured with curren...
What is the current status of trial NCT06702033?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2025-04-10. Estimated completion is 2033-07-15.
What conditions does trial NCT06702033 study?
This clinical trial studies the following conditions: HPV-Related Oropharynx Squamous Cell Carcinoma.
What interventions are being tested in trial NCT06702033?
The interventions under investigation include: Cisplatin (DRUG), Surgery (PROCEDURE), Radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT06702033?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06702033 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.